These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 30266498)
1. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2. Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498 [TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells. Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623 [TBL] [Abstract][Full Text] [Related]
3. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. Yagi Y; Fushida S; Harada S; Kinoshita J; Makino I; Oyama K; Tajima H; Fujita H; Takamura H; Ninomiya I; Fujimura T; Ohta T; Yashiro M; Hirakawa K J Exp Clin Cancer Res; 2010 Nov; 29(1):149. PubMed ID: 21080974 [TBL] [Abstract][Full Text] [Related]
4. Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer. Xiong K; Zhang H; Du Y; Tian J; Ding S Exp Mol Med; 2019 Aug; 51(8):1-15. PubMed ID: 31451695 [TBL] [Abstract][Full Text] [Related]
5. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986 [TBL] [Abstract][Full Text] [Related]
6. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Kim JK; Noh JH; Eun JW; Jung KH; Bae HJ; Shen Q; Kim MG; Chang YG; Kim SJ; Park WS; Lee JY; Borlak J; Nam SW Mol Cancer Res; 2013 Jan; 11(1):62-73. PubMed ID: 23175521 [TBL] [Abstract][Full Text] [Related]
7. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells. Jahani M; Khanahmad H; Nikpour P J Gastrointest Cancer; 2021 Jun; 52(2):676-681. PubMed ID: 32621111 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Bracker TU; Sommer A; Fichtner I; Faus H; Haendler B; Hess-Stumpp H Int J Oncol; 2009 Oct; 35(4):909-20. PubMed ID: 19724929 [TBL] [Abstract][Full Text] [Related]
10. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988 [TBL] [Abstract][Full Text] [Related]
11. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits. Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187 [TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. Gong Y; Ren J; Liu K; Tang LM World J Gastroenterol; 2015 Mar; 21(10):2949-58. PubMed ID: 25780292 [TBL] [Abstract][Full Text] [Related]
13. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375 [TBL] [Abstract][Full Text] [Related]
14. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525 [TBL] [Abstract][Full Text] [Related]
15. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870 [TBL] [Abstract][Full Text] [Related]
16. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734 [TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158 [TBL] [Abstract][Full Text] [Related]
18. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines. Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085 [TBL] [Abstract][Full Text] [Related]
20. Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. Sun J; Piao J; Li N; Yang Y; Kim KY; Lin Z FEBS J; 2020 May; 287(10):2118-2133. PubMed ID: 31692265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]